Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Icecure Medical ( (ICCM) ) has issued an update.
IceCure Medical participated in the 2025 Society of Interventional Oncology Annual Meeting, highlighting their ProSense® cryoablation system through award-winning studies and hands-on training sessions for breast cancer treatment. The company anticipates the FDA’s market authorization decision in Q1 2025, which could significantly impact their market positioning and adoption, especially in the U.S. where interest among medical professionals is growing.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, specializes in developing and marketing advanced cryoablation therapy systems using liquid nitrogen to destroy tumors. Their primary focus is on breast, kidney, bone, and lung cancer. The minimally invasive technology offers a safe alternative to surgical tumor removal and is marketed globally with approvals in the U.S., Europe, and China.
YTD Price Performance: 1.63%
Average Trading Volume: 643,967
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $70.71M
For an in-depth examination of ICCM stock, go to TipRanks’ Stock Analysis page.
